Lv1
80 积分 2024-10-18 加入
A new liver-targeted agonist of thyroid hormone receptor beta resmetirom in treating MASLD/MASH: From mechanism to therapy
1个月前
已完结
Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities
1个月前
已完结
Mitochondrial dysfunction in non-alcoholic fatty liver disease and insulin resistance: Cause or consequence?
1个月前
已完结
Cardiac Hypertrophy: The Good, the Bad, and the Ugly
1个月前
已完结
Resmetirom: First Approval
3个月前
已完结
Hepatic thyroid hormone receptor‐β signalling: Mechanisms and recent advancements in the treatment of metabolic dysfunction‐associated steatohepatitis
3个月前
已完结
Super-dosed butyrate induces a revisable metabolic paralysis through transient mitochondrial reprogramming in the gut-brain axis
6个月前
已关闭
Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist #
7个月前
已完结
Caffeic acid ameliorates metabolic dysfunction-associated steatotic liver disease via alleviating oxidative damage and lipid accumulation in hepatocytes through activating Nrf2 via targeting Keap1
8个月前
已完结
Elafibranor and nitazoxanide synergize to reduce fibrosis in a NASH model
8个月前
已完结
Assessing antimicrobial resistance connectivity across One Health sectors
皖公网安备34019202002308
